Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis.

Lifen CaoRobert ShenkNickolas StabelliniMegan E MillerChristopher W ToweAlberto J Montero

Published in: Breast cancer research and treatment (2021)

Even though there is a modest OS advantage favoring adjuvant chemo-HER2 therapy in patients with pT1N0 HER2+ BC, HER2 monotherapy was associated with 5-year OS > 90%. Therefore, in select patients who have contraindications for cytotoxic chemotherapy, or decline adjuvant chemotherapy altogether, adjuvant trastuzumab monotherapy appears to be a reasonable alternative.

Keyphrases

early stage
locally advanced
epidermal growth factor receptor
newly diagnosed
ejection fraction
open label
photodynamic therapy
metastatic breast cancer
rectal cancer
squamous cell carcinoma
patient reported outcomes
mesenchymal stem cells
cell therapy
cancer therapy
bone marrow
drug induced
double blind